Horizon Pharma PLC (HZNP) Given a $18.00 Price Target by Piper Jaffray Companies Analysts
Piper Jaffray Companies set a $18.00 target price on Horizon Pharma PLC (NASDAQ:HZNP) in a research note published on Sunday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on the company. BidaskClub upgraded Horizon Pharma PLC from a hold rating to a buy rating in a research note on Saturday, June 24th. Cantor Fitzgerald set a $13.00 price target on Horizon Pharma PLC and gave the company a buy rating in a research note on Monday, July 31st. ValuEngine lowered Horizon Pharma PLC from a buy rating to a hold rating in a research note on Friday, September 1st. Jefferies Group LLC restated a buy rating and set a $14.00 price target on shares of Horizon Pharma PLC in a research note on Friday, July 14th. Finally, Zacks Investment Research upgraded Horizon Pharma PLC from a strong sell rating to a hold rating in a research note on Tuesday, July 11th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Horizon Pharma PLC currently has a consensus rating of Buy and an average target price of $18.67.
Shares of Horizon Pharma PLC (HZNP) opened at 12.71 on Friday. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The company’s 50 day moving average price is $12.88 and its 200-day moving average price is $13.08. The firm’s market capitalization is $2.08 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The firm had revenue of $289.51 million for the quarter, compared to analyst estimates of $237.01 million. During the same period in the previous year, the company posted $0.56 earnings per share. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. On average, equities analysts predict that Horizon Pharma PLC will post $1.08 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Horizon Pharma PLC (HZNP) Given a $18.00 Price Target by Piper Jaffray Companies Analysts” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/14/horizon-pharma-plc-hznp-given-a-18-00-price-target-by-piper-jaffray-companies-analysts.html.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of Horizon Pharma PLC by 68,479.5% in the 1st quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock worth $196,001,000 after acquiring an additional 13,241,875 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Horizon Pharma PLC by 119.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after acquiring an additional 3,409,411 shares in the last quarter. William Blair Investment Management LLC acquired a new position in shares of Horizon Pharma PLC in the 2nd quarter worth approximately $23,557,000. Balyasny Asset Management LLC acquired a new position in shares of Horizon Pharma PLC in the 2nd quarter worth approximately $13,958,000. Finally, Highbridge Capital Management LLC boosted its holdings in shares of Horizon Pharma PLC by 128.2% in the 1st quarter. Highbridge Capital Management LLC now owns 1,545,169 shares of the biopharmaceutical company’s stock worth $22,837,000 after acquiring an additional 867,927 shares in the last quarter. Institutional investors own 82.30% of the company’s stock.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.